福建吉諾霍普生物科技有限公司成立于 2019 年，由新希望豪森卡兄弟和臺灣吉諾維奧生物科技股份有限公司共同創(chuàng)立。公司位于福建省莆田市國家“海峽兩岸生物技術(shù)與健康醫(yī)療產(chǎn)業(yè)合作區(qū)”。公司現(xiàn)有員工 220 人，2023 年，公司入選福建省專精特新企業(yè)。

該公司專注于高效多肽 API/溶液，并向全球市場銷售多肽 API/溶液和制劑生產(chǎn)服務。公司總占地面積55畝，總建筑面積約70000平方米，建有研發(fā)中心約800平方米，質(zhì)量控制中心1000平方米，GMP生產(chǎn)車間3300平方米。目前已建成11條生產(chǎn)線，其中重組肽原料藥和全合成肽原料藥制備生產(chǎn)線5條，注射液生產(chǎn)線6條。此外，公司還擁有大型抗腫瘤注射車間、小型多用途注射車間、大型多用途注射車間。生產(chǎn)線的建設(shè)和運營管理滿足全球藥品市場的監(jiān)管要求，滿足中美雙注冊申報。也可滿足國內(nèi)外客戶的注冊和銷售。

產(chǎn)品優(yōu)勢：

目前，公司主要產(chǎn)品有索馬魯肽、Tirzepatide、美容藥微球、膠原蛋白。特別是，公司具有成熟的 Semaglutide API 2 工藝制備優(yōu)勢，Semaglutide API 在美國 FDA 注冊（DMF 編號：040957），Tirzepatide API 在美國 FDA 注冊（DMF 編號：040503），

索馬魯肽 API 具有以下三個特點：價格低、質(zhì)量高、產(chǎn)能（噸位）大。Tirzepatide API 在多肽制藥行業(yè)廣受好評。

    Fujian Genohope Biotech Ltd., is founded by New Hope Group, a Fortune Global 500 company, together with Genovior, fomous Taiwan peptide company and now a member of the Polaris Pharma Group, as the  globalized center for R&D and production of peptide products, located in the National Biotech and Health Industry Zone of Across-Strait in Putian City, Fujian Province. 
   The company focuses on the research and development and production of high potency polypeptide products, targeting the global market, and provides polypeptide API/raw material and preparation products. It has built polypeptide API workshops, bio-fermentation workshops, polypeptide purification and lyophilization workshops, and multifunctional injection workshops that meet the GMP requirements of mainstream markets such as the U.S. FDA, EU EMA, Japanese PMDA, and China NMPA. With the strong support of New Hope Group, the company has introduced advanced large-scale CS-PREP® industrial preparative liquid chromatography systems, becoming one of the few polypeptide companies in the industry with  a capacity of tons.

    In 2023, Genehope has been rewarded as Specialized and Novel Enterprise of Fujian Province.
In 2023 June, the US FDA completed its first on-site inspection for Genohope.